The Molecular Microbiology group has strengths in the development of platforms for the discovery of new antimicrobials, as well as in basic research on dormant persister cells, uncultured bacteria, human and environmental microbiomes, mechanism of mutagenesis, microbial development and biofilm formation. The group is interested in understanding the rise of multidrug resistant pathogens and the threat of genetically engineered bioweapons. Hence the focus of this group intersects strongly with that of the University in the areas of health and security. The group has papers in high-profile Journals (Nature, Science, PNAS, PloSBiology, PloSPathogens), substantial funding including grants from NIH, NSF, the Gates Foundation and the Pfeiffer Foundation, and a correspondingly large number of team members and collaborators. Dr. Lewis, a member of this group, directs the Antimicrobial Discovery Center (ADC) located in the Biology Department. Two biotech companies, NovoBiotic Pharmaceuticals and Arietis Corporation are spinoffs from the technologies developed at Northeastern and work in collaboration with the Center.